DGX QUEST DIAGNOSTICS INC

NYSE questdiagnostics.com


$ 177.37 $ 0.00 (0 %)    

Wednesday, 29-Oct-2025 06:40:05 EDT
QQQ $ 635.26 $ 0.00 (0 %)
DIA $ 477.81 $ 0.00 (0 %)
SPY $ 688.55 $ 0.00 (0 %)
TLT $ 91.99 $ 0.00 (0 %)
GLD $ 370.67 $ 0.00 (0 %)
$ 178.28
$ 179.80
$ 177.39 x 56
$ 182.25 x 136
-- - --
$ 146.30 - $ 197.55
1,434,053
na
19.83B
$ 0.41
$ 20.47
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-21-2025 09-30-2025 10-Q
2 07-23-2025 06-30-2025 10-Q
3 04-23-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 10-23-2024 09-30-2024 10-Q
6 07-24-2024 06-30-2024 10-Q
7 04-24-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 10-25-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 04-28-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 10-21-2022 09-30-2022 10-Q
14 07-22-2022 06-30-2022 10-Q
15 04-22-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 10-22-2021 09-30-2021 10-Q
18 07-23-2021 06-30-2021 10-Q
19 04-23-2021 03-31-2021 10-Q
20 02-22-2021 12-31-2020 10-K
21 10-23-2020 09-30-2020 10-Q
22 07-24-2020 06-30-2020 10-Q
23 05-04-2020 03-31-2020 10-Q
24 02-20-2020 12-31-2019 10-K
25 10-23-2019 09-30-2019 10-Q
26 07-24-2019 06-30-2019 10-Q
27 04-24-2019 03-31-2019 10-Q
28 02-21-2019 12-31-2018 10-K
29 10-24-2018 09-30-2018 10-Q
30 07-25-2018 06-30-2018 10-Q
31 04-20-2018 03-31-2018 10-Q
32 02-23-2018 12-31-2017 10-K
33 10-19-2017 09-30-2017 10-Q
34 07-25-2017 06-30-2017 10-Q
35 04-21-2017 03-31-2017 10-Q
36 02-22-2017 12-31-2016 10-K
37 10-21-2016 09-30-2016 10-Q
38 07-25-2016 06-30-2016 10-Q
39 04-27-2016 03-31-2016 10-Q
40 02-26-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 quest-diagnostics-new-blood-tests-accurately-detect-alzheimers-study-finds

Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in sy...

 barclays-maintains-equal-weight-on-quest-diagnostics-raises-price-target-to-195

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from...

 truist-securities-maintains-hold-on-quest-diagnostics-raises-price-target-to-205

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target fro...

 leerink-partners-maintains-outperform-on-quest-diagnostics-raises-price-target-to-210

Leerink Partners analyst Michael Cherny maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target...

 quest-diagnostics-reports-q3-earnings-shares-slide

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings resu...

 gold-sinks-5-on-worst-day-in-5-years-dow-jones-hits-record-highs-whats-moving-markets-tuesday

Gold prices suffered a sharp correction on Tuesday as investors locked in profits following this year's explosive rally, wh...

 quest-diagnostics-q3-adj-eps-260-beats-250-estimate-sales-2816b-beat-2736b-estimate

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.60 per share which beat the analyst consensus estimate of $2.50 ...

 quest-diagnostics-lowers-fy2025-gaap-eps-guidance-from-860-880-to-858-866-vs-868-est

Quest Diagnostics (NYSE:DGX) lowers FY2025 GAAP EPS guidance from $8.60-$8.80 to $8.58-$8.66 vs $8.68 analyst estimate..

 quest-diagnostics-raises-fy2025-adj-eps-guidance-from-963-983-to-976-984-vs-975-est-raises-fy2025-sales-guidance-from-10800b-10920b-to-10960b-11000b-vs-10865b-est

Quest Diagnostics (NYSE:DGX) raises FY2025 Adj EPS guidance from $9.63-$9.83 to $9.76-$9.84 vs $9.75 analyst estimate. Raises F...

 ubs-maintains-neutral-on-quest-diagnostics-raises-price-target-to-190

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $180 to $190.

 mizuho-maintains-outperform-on-quest-diagnostics-raises-price-target-to-210

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $190 to $...

 evercore-isi-group-maintains-in-line-on-quest-diagnostics-raises-price-target-to-190

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Line and raises the price tar...

Core News & Articles

Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest&...

 quest-diagnostics-expands-epic-integration-with-aura-beaker-mychart-and-billing-systems-to-streamline-national-laboratory-operations

With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the custome...

 quest-diagnostics-announces-advanced-pharmacogenomic-laboratory-test-service-to-guide-drug-therapy-based-on-genetic-response

New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialtie...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION